Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PROTECT-1: Ziextenzo vs Neulasta in Breast Cancer
NCT01735175Phase 3Completed
- Sponsor
- Sandoz
- Start
- Jun 2012
- Primary completion
- May 2013
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 6
01
Overview
A Phase 3 trial of pegfilgrastim in chemotherapy-induced neutropenia (CIN), sponsored by Sandoz. Started Jun 2012; status: completed.
02
Drugs
pegfilgrastim
03
Conditions
chemotherapy-induced neutropenia (CIN)
Beyond the preview
Go deeper on NCT01735175.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01735175.